Clinical Research Directory
Browse clinical research sites, groups, and studies.
Itraconazole to Prevent Recurrent Barrett's Esophagus
Sponsor: University of Kansas Medical Center
Summary
Recurrent Barrett's esophagus (BE) that occurs at the rate of 12.4%/year is the Achilles heel of the endoscopic treatment of high-risk BE. Over time, after eradication, BE ultimately recurs in as many as 30-50% of the patients putting them at risk for esophageal adenocarcinoma (EAC), thereby undoing the benefits of an effective initial therapy. Also, recurrences need retreatments that increase costs and complications including strictures and refractory ulcerations. A therapy to prevent recurrent BE does not currently exist. Itraconazole with its ability to inhibit important molecular pathways related to BE development could enhance the long-term effectiveness of endoscopic eradication of high-risk BE, thereby promoting a long-term cure
Official title: Itraconazole Repurposing to Reduce Residual Cancer Risk in Patients With High-risk Barrett's Esophagus After Ablation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2022-09-14
Completion Date
2026-06-30
Last Updated
2025-08-08
Healthy Volunteers
No
Conditions
Interventions
Itraconazole in capsule form
Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).
Itraconazole in solution form
Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
Locations (1)
University of Kansas Medical Center
Kansas City, Kansas, United States